{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:01:18Z","timestamp":1772024478590,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T00:00:00Z","timestamp":1415923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T00:00:00Z","timestamp":1415923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s12032-014-0251-x","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T11:09:48Z","timestamp":1415963388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["RETRACTED ARTICLE: A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients"],"prefix":"10.1007","volume":"31","author":[{"given":"Jun","family":"Yao","sequence":"first","affiliation":[]},{"given":"Jian-yao","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Ying-xue","family":"Li","sequence":"additional","affiliation":[]},{"given":"Ru","family":"Zhang","sequence":"additional","affiliation":[]},{"given":"Li-Sheng","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,11,14]]},"reference":[{"issue":"10","key":"251_CR1","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","volume":"19","author":"TR Halfdanarson","year":"2008","unstructured":"Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19(10):1727\u201333. doi:10.1093\/annonc\/mdn351.","journal-title":"Ann Oncol"},{"issue":"5","key":"251_CR2","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1634\/theoncologist.2008-0259","volume":"14","author":"F Ehehalt","year":"2009","unstructured":"Ehehalt F, Saeger HD, Schmidt CM, Grutzmann R. Neuroendocrine tumors of the pancreas. Oncologist. 2009;14(5):456\u201367. doi:10.1634\/theoncologist.2008-0259.","journal-title":"Oncologist"},{"issue":"18","key":"251_CR3","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372. doi:10.1200\/JCO.2007.15.4377.","journal-title":"J Clin Oncol"},{"issue":"5","key":"251_CR4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/ijc.25426","volume":"128","author":"Q Ben","year":"2011","unstructured":"Ben Q, Wang K, Yuan Y, Li Z. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case\u2013control study. Int J Cancer. 2011;128(5):1179\u201386. doi:10.1002\/ijc.25426.","journal-title":"Int J Cancer"},{"issue":"8","key":"251_CR5","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/j.1572-0241.1998.401_w.x","volume":"93","author":"KY Lam","year":"1998","unstructured":"Lam KY, Lo CY. Role of p53 tumor suppressor gene in pancreatic endocrine tumors of Chinese patients. Am J Gastroenterol. 1998;93(8):1232\u20135. doi:10.1111\/j.1572-0241.1998.401_w.x.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"251_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.critrevonc.2009.01.008","volume":"72","author":"G Capurso","year":"2009","unstructured":"Capurso G, Fazio N, Festa S, Panzuto F, De Braud F, Delle Fave G. Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives. Crit Rev Oncol\/Hematol. 2009;72(2):110\u201324. doi:10.1016\/j.critrevonc.2009.01.008.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"1","key":"251_CR7","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1677\/ERC-09-0108","volume":"17","author":"B Basu","year":"2010","unstructured":"Basu B, Sirohi B, Corrie P. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin. Endocr Relat Cancer. 2010;17(1):R75\u201390. doi:10.1677\/ERC-09-0108.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"251_CR8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.6004\/jnccn.2009.0050","volume":"7","author":"OH Clark","year":"2009","unstructured":"Clark OH, Benson AB 3rd, Berlin JD, Choti MA, Doherty GM, Engstrom PF, et al. NCCN clinical practice guidelines in oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009;7(7):712\u201347.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"251_CR9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1517\/13543780902850432","volume":"18","author":"D Granberg","year":"2009","unstructured":"Granberg D. Investigational drugs for neuroendocrine tumours. Expert Opin Investig Drugs. 2009;18(5):601\u20138. doi:10.1517\/13543780902850432.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"251_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","volume":"86","author":"PN Cheng","year":"1999","unstructured":"Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86(6):944\u20138.","journal-title":"Cancer"},{"issue":"5","key":"251_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/01.coc.0000135343.06038.eb","volume":"27","author":"AD McCollum","year":"2004","unstructured":"McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004;27(5):485\u20138.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"251_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","volume":"28","author":"E Missiaglia","year":"2010","unstructured":"Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28(2):245\u201355. doi:10.1200\/JCO.2008.21.5988.","journal-title":"J Clin Oncol"},{"issue":"1","key":"251_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","volume":"28","author":"JC Yao","year":"2010","unstructured":"Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69\u201376. doi:10.1200\/JCO.2009.24.2669.","journal-title":"J Clin Oncol"},{"issue":"26","key":"251_CR14","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311\u20138. doi:10.1200\/JCO.2008.16.7858.","journal-title":"J Clin Oncol"},{"issue":"6","key":"251_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl J Med. 2011;364(6):514\u201323. doi:10.1056\/NEJMoa1009290.","journal-title":"New Engl J Med"},{"issue":"10","key":"251_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/jjco\/hys123","volume":"42","author":"T Ito","year":"2012","unstructured":"Ito T, Okusaka T, Ikeda M, Igarashi H, Morizane C, Nakachi K, et al. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol. 2012;42(10):903\u201311. doi:10.1093\/jjco\/hys123.","journal-title":"Jpn J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s12032-015-0661-4","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000},"record-id":"3640"},{"DOI":"10.1007\/s12032-015-0661-4","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T00:00:00Z","timestamp":1437436800000}},{"DOI":"10.1007\/s12032-014-0251-x","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T00:00:00Z","timestamp":1415923200000}}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0251-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-014-0251-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0251-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0251-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:06:29Z","timestamp":1772021189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-014-0251-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,14]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1007\/s12032-014-0251-x","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,14]]},"assertion":[{"value":"19 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"251"}}